Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CT053 anti-BCMA autologous CAR T cells in relapsed/refractory multiple myeloma
CTR20190955Phase 2Active
- Sponsor
- CARsgen Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ningetinib in multiple myeloma (MM), sponsored by CARsgen Therapeutics. Started Aug 2019; status: active.
02
Drugs
ningetinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20190955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190955.